Welcome to the Definitive Platform for Advancing TIL Therapy Drug Development
With TIL therapies rapidly expanding beyond melanoma and a new generation of engineered, persistent, and precisely characterized TILs reaching patients worldwide, the 7th TIL Therapies Summit was your golden opportunity to reconnect with peers, gain exclusive insights you won’t find anywhere else, and discover how leading organizations are evolving in this dynamic field.
Whether you're preparing for your first clinical trial, seeking innovative strategies to optimize TIL manufacturing, or navigating the real-world operational challenges of rolling out these therapies at scale, this summit was the one-stop shop for everything TIL.
Highlights of the 7th TIL Therapies Summit Included
Exclusive Clinical Insights
Discover exclusive clinical insights from biotech frontrunners KSQ Therapeutics and Obsidian Therapeutics, as they reveal how their next-generation TIL therapies are expanding patient access through multicenter trials.
Real-World Perspectives
Explore real-world perspectives from both sides of the treatment journey in a compelling panel led by Dr. Roda Amaria from MD Anderson Cancer Center, featuring clinicians and actual TIL patients sharing firsthand experiences.
Manufacturing Strategy
Streamline your manufacturing strategy with proven innovations in closed systems, faster turnaround times, and reduced reliance on IL-2 for expansion, enabling safer, more scalable, and patient-friendly TIL production.
TIL Innovation
Unlock the next wave of TIL innovation by learning how leading R&D teams are engineering therapies to overcome the toughest challenges in persistence, specificity, and potency within the tumor microenvironment.
Global Clinical Strategy
Accelerate your global clinical strategy with regulatory insights from experts who’ve successfully navigated approvals with the FDA, EMA, Health Canada, and China’s NMPA, giving you a clear roadmap for international expansion.
Attending Companies Included